Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8929772rdf:typepubmed:Citationlld:pubmed
pubmed-article:8929772lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:8929772lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8929772lifeskim:mentionsumls-concept:C0014442lld:lifeskim
pubmed-article:8929772lifeskim:mentionsumls-concept:C0005516lld:lifeskim
pubmed-article:8929772lifeskim:mentionsumls-concept:C0030817lld:lifeskim
pubmed-article:8929772lifeskim:mentionsumls-concept:C0030946lld:lifeskim
pubmed-article:8929772lifeskim:mentionsumls-concept:C0165519lld:lifeskim
pubmed-article:8929772lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:8929772lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:8929772lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:8929772pubmed:issue1lld:pubmed
pubmed-article:8929772pubmed:dateCreated1997-4-2lld:pubmed
pubmed-article:8929772pubmed:abstractTextThe direct and indirect inhibitory potential of D-penicillamine toward human neutrophil and synovial fluid gelatinase B, a marker enzyme for disease severity in RA, was investigated. Gelatinase and plasminogen activator activities were assessed by SDS-polyacrylamide gel electrophoresis zymography. D-penicillamine significantly inhibits purified and synovial fluid gelatinase B in vitro at concentrations attainable in vivo and also blocks in vitro plasminogen activation. Protease inhibition may be a mechanism of action for D-penicillamine as DMARD.lld:pubmed
pubmed-article:8929772pubmed:languageenglld:pubmed
pubmed-article:8929772pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8929772pubmed:citationSubsetIMlld:pubmed
pubmed-article:8929772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8929772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8929772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8929772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8929772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8929772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8929772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8929772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8929772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8929772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8929772pubmed:statusMEDLINElld:pubmed
pubmed-article:8929772pubmed:monthJanlld:pubmed
pubmed-article:8929772pubmed:issn0770-3198lld:pubmed
pubmed-article:8929772pubmed:authorpubmed-author:OpdenakkerGGlld:pubmed
pubmed-article:8929772pubmed:authorpubmed-author:MasureSSlld:pubmed
pubmed-article:8929772pubmed:authorpubmed-author:PaemenLLlld:pubmed
pubmed-article:8929772pubmed:authorpubmed-author:GrilletBBlld:pubmed
pubmed-article:8929772pubmed:authorpubmed-author:NorgaKKlld:pubmed
pubmed-article:8929772pubmed:issnTypePrintlld:pubmed
pubmed-article:8929772pubmed:volume15lld:pubmed
pubmed-article:8929772pubmed:ownerNLMlld:pubmed
pubmed-article:8929772pubmed:authorsCompleteYlld:pubmed
pubmed-article:8929772pubmed:pagination31-4lld:pubmed
pubmed-article:8929772pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:meshHeadingpubmed-meshheading:8929772-...lld:pubmed
pubmed-article:8929772pubmed:year1996lld:pubmed
pubmed-article:8929772pubmed:articleTitleHuman gelatinase B, a marker enzyme in rheumatoid arthritis, is inhibited by D-penicillamine: anti-rheumatic activity by protease inhibition.lld:pubmed
pubmed-article:8929772pubmed:affiliationRega Institute for Medical Research, Leuven, Belgium.lld:pubmed
pubmed-article:8929772pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8929772pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:8929772pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed